Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Wednesday morning. The brokerage issued a sell rating on the stock.

A number of other analysts have also commented on the stock. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $1.81 on Wednesday. The company has a market cap of $6.41 million, a PE ratio of -1.01 and a beta of 1.33. The stock has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $1.98. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.